Uncertainty regarding exemption from infringement for studies after approval, or not required, by the US FDA

Author： Grossman Jonathan E   Hanish John P  

Publisher： Future Science

ISSN： 2046-8954

Source： Pharmaceutical Patent Analyst, Vol.2, Iss.4, 2013-07, pp. : 435-437

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

US FDA shows its teeth with Rotarix approval

By  

Reactions Weekly, Vol. 1, Iss. 1200, 2008-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

News from the US FDA

By  

Inpharma, Vol. 1, Iss. 1237, 2000-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite

Endo Pharmaceuticals received a "not approvable" letter from the US FDA regarding their supplemental New Drug Application for frovatriptan [Frova]

By  

Inpharma, Vol. 1, Iss. 1609, 2007-01 ,pp. : 23-23

Adis International

Access to resources Recommend Favorite

Clamp down on Rx drugs without US FDA approval

By  

Reactions Weekly, Vol. 1, Iss. 1106, 2006-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Efavirenz [`Sustiva'] is the first antiretroviral to be granted traditional (full) approval by the US FDA

By  

Inpharma, Vol. 1, Iss. 1226, 2000-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite